Centralized Pan-South African Survey on the Undertreatment of Hypercholesterolaemia (CEPHEUS)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01027624
First received: December 4, 2009
Last updated: April 14, 2011
Last verified: April 2011

December 4, 2009
April 14, 2011
November 2009
April 2010   (final data collection date for primary outcome measure)
Proportion of patients on lipid-lowering pharmacological treatment reaching LDL-C goals according to NCEP ATP III/Updated 2004 NCEP ATP III [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01027624 on ClinicalTrials.gov Archive Site
  • Proportion of patients on lipid-lowering pharmacological treatment reaching LDL-C goals according to NCEP ATP III/Updated 2004 NCEP ATP III [ Designated as safety issue: No ]
  • Proportion of patients on lipid-lowering pharmacological treatment reaching LDL-C goals according to the Fourth Joint European Task Force Guidelines/South African Guidelines in primary/secondary prevention patients, patients with metabolic syndrome [ Designated as safety issue: No ]
  • Proportion of patients on lipid-lowering pharmacological treatment reaching the non HDL-C goals according to NCEP ATP III/Updated 2004 NCEP ATP III Guidelines [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Centralized Pan-South African Survey on the Undertreatment of Hypercholesterolaemia
Centralized Pan-South African Survey on the Undertreatment of Hypercholesterolaemia.

This is a multi-centre survey of patients who are currently on lipid lowering pharmacological treatment in South Africa.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Serum

Probability Sample

Multi-centre survey of patients who are currently on lipid-lowering pharmacological treatment in South Africa.

Undertreatment of Hypercholesterolaemia
Not Provided
Hyperchlesterolaemia
Participants undertreated with hypercholesterolaemia
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
3000
April 2010
April 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject must be 18 years of age or older of either gender or race.
  • Subject must provide informed consent and comply with the survey procedures.
  • Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

Exclusion Criteria:

  • Subjects who are unwilling or unable to provide informed consent.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
South Africa
 
NCT01027624
NIS-CZA-DUM-2009/1
Yes
MC MD, AstraZeneca Pharmaceuticals Pty Ltd
AstraZeneca
Not Provided
Principal Investigator: Prof F Raal National Co-ordinator
AstraZeneca
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP